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1 (GIT-1), is thought to serve as a signaling scaffold/adaptor
protein that binds a number of different protein partners to
mediate actin cytoskeletal changes and cell migration (1–3). It
also functions as a GAP for Arf1 and Arf6, two members of the
Arf family of small GTPases that have been implicated in the
regulation of trafficking events in cells (4 – 6). Recently, we
found that Cat-1 is overexpressed in a large number of human
cervical carcinomas and that knocking down its expression in
HeLa cells using siRNAs blocked the ability of these cells to
exhibit anchorage-independent growth (6) (i.e. as assayed by
colony formation in soft agar), a hallmark of cancer and transformed cells (7). We then went on to show that introducing an
siRNA-insensitive form of wild-type Cat-1 into HeLa cells,
where endogenous Cat-1 expression was knocked down,
restored their ability to form colonies in soft agar. On the other
hand, introducing an siRNA-insensitive mutant form of Cat-1,
defective in binding paxillin, was unable to restore this transformed phenotype. These findings indicated that the interaction between Cat-1 and paxillin was critical for the Cat-1-mediated anchorage-independent growth of HeLa cells.
Paxillin is another signaling scaffold/adapter protein that has
been shown to play important roles in regulating focal adhesion
dynamics and integrin-mediated signaling events (8). As one of
the first proteins to be identified as a constituent of focal complexes (9), paxillin was shown to accumulate at nascent focal
complexes in migrating cells (10). It was also demonstrated
through mutagenesis studies that disrupting the phosphorylation of paxillin by tyrosine kinases such as the focal adhesion
kinase or blocking the ability of paxillin to interact with proteins
like Cat or tubulin, alters focal complex dynamics, resulting in
irregular cell spreading and defects in cell migration (11, 12).
In addition to being important for the adhesion and migration of a wide variety of cell types, various reports have also
implicated paxillin in the growth and survival of certain forms
of human cancer. Indeed, the transcript and protein levels of
paxillin are frequently up-regulated in several types of cancer,
including oral, bone, and colorectal tumors (13–17). In colorectal tumors, survival analyses performed on patients revealed a
correlation between the extent of paxillin expression and clinical outcome; the prognosis of patients showing a relatively high
expression of paxillin was poorer compared with those with low
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Cool-associated tyrosine-phosphorylated protein 1 (Cat-1)
is a signaling scaffold as well as an ADP-ribosylation factorGTPase-activating protein. Although best known for its role in
cell migration, we recently showed that the ability of Cat-1 to
bind paxillin, a major constituent of focal complexes, is also
essential for the anchorage-independent growth of HeLa cervical carcinoma cells. Here we set out to learn more about the
underlying mechanism by which Cat-paxillin interactions
mediate this effect. We show that knocking down paxillin
expression in HeLa cells promotes their ability to form colonies
in soft agar, whereas ectopically expressing paxillin in these cells
inhibits this transformed growth phenotype. Although knocking down Cat-1 prevents HeLa cells from forming colonies in
soft agar, when paxillin is knocked down together with Cat-1,
the cells are again able to undergo anchorage-independent
growth. These results suggest that the requirement of Cat-1 for
this hallmark of cellular transformation is coupled to its ability
to bind paxillin and abrogate its actions as a negative regulator
of anchorage-independent growth. We further show that
knocking down Cat-1 expression in HeLa cells leads to a reduction in Akt activation, which can be reversed by knocking down
paxillin. Moreover, expression of constitutively active forms of
Akt1 and Akt2 restores the anchorage-independent growth
capability of HeLa cells depleted of Cat-1 expression. Together,
these findings highlight a novel mechanism whereby interactions between Cat-1 and its binding partner paxillin are necessary to ensure sufficient Akt activation so that cancer cells are
able to grow under anchorage-independent conditions.

Cat-1/Git-1 Binds Paxillin and Promotes AKT Activation

FIGURE 1. Paxillin negatively regulates the anchorage-independent
growth of HeLa cells. A, images of HeLa cells that had been either mocktransfected or transfected with GFP-Pxn WT, as indicated, and then stained
with GFP and Cat-1 antibodies. Arrows indicate some of the focal complexes
where both GFP-tagged Pxn WT and Cat-1 were detected. B and C, two sets of
HeLa cells were transfected with either Cont. siRNA or Pxn siRNA 1 or Pxn
siRNA 2. One set (B) was lysed and then immunoblotted with Pxn and Cat-1
antibodies. Soft agar assays were performed (C) on the other set of cells. The
number of colonies that formed for each condition was determined. D and E,
two sets of NIH3T3 cells stably expressing an activated form of Cdc42, Cdc42
F28L, were transfected with either Cont. siRNA or Pxn siRNA 1 as indicated.
One set (D) was lysed and then immunoblotted with Pxn and Cat-1 antibodies. Soft agar assays were performed (E) on the other set of cells. The number
of colonies that formed for each condition was determined. All of the experiments shown were performed three separate times, each yielding similar
results. The data shown in C and E represent mean ⫾ S.D. Student’s t tests
were performed. *, p ⬍ 0.05.

Results
Knocking Down Paxillin Expression Enhances Anchorage-independent Growth—The Cat-1-mediated anchorage-independent growth of HeLa cervical carcinoma cells is dependent on
its ability to bind paxillin, a major scaffold/adaptor protein
found in focal complexes (6). Here we wanted to build upon
these findings by determining the mechanism by which Cat-1paxillin interactions promote this transformed phenotype. To
begin, HeLa cells that had been either mock-transfected or
transfected with a construct encoding a GFP-tagged form of
wild-type paxillin (GFP-Pxn WT) to label focal complexes were
stained with GFP and Cat-1 antibodies. Fig. 1A shows that little
GFP signal was detected in mock-transfected cells (Mock
Transfected, GFP), whereas Cat-1 was expressed in structures
that resembled focal complexes (Mock Transfected, Cat-1).
When paxillin was ectopically expressed in the cells, it localized
with Cat-1 (Fig. 1A, Transfected with GFP-Pxn WT, GFP and

Cat-1), confirming that both of these proteins do indeed reside
in focal complexes.
We introduced a control siRNA or two different siRNAs targeting paxillin into HeLa cells and then assayed the ability of
these cells to form colonies in soft agar (i.e. anchorage-independent growth). Fig. 1B, top panel, shows that both paxillin
siRNAs (Pxn siRNA 1 and Pxn siRNA 2) knocked down endogenous paxillin expression compared with the control siRNA
(Cont. siRNA). Pxn siRNA 1 reduced paxillin levels by ⬃70%,
whereas Pxn siRNA 2 consistently reduced paxillin expression
by ⬃95%. Given the findings from several studies linking paxillin to cell growth and survival, we initially suspected that
knocking down paxillin in HeLa cells would compromise their
ability to grow in soft agar. However, Fig. 1C shows that this was
not the case. In fact, knocking down paxillin expression led to
the formation of more colonies in soft agar compared with cancer cells expressing control siRNA (Fig. 1C, compare the Cont.
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paxillin expression (16). In such cases, the potential roles of
paxillin in cell migration and invasiveness are likely to come
into play in the development of these aggressive cancers. It has
also been reported that paxillin can contribute to the promotion of anchorage-independent growth of certain colon cancer
cell lines, DLD1 and HCT116, as well as fibroblasts stably
expressing the constitutively active H-Ras G12V mutant (16,
18). However, there has also been a report where paxillin
expression was negatively correlated with metastasis (19), and,
as described below, how paxillin contributes to the ability of
cancer cells to exhibit anchorage-independent growth appears
to be context-dependent.
In this study, we set out to understand the underlying mechanism by which the paxillin binding partner, Cat-1, promoted
the anchorage-independent growth of human cervical carcinoma cells (6). Given our previous findings highlighting an
essential role played by Cat-1 in HeLa cell transformation (6),
together with the suggestions that paxillin contributes to cancer progression (13–18), we initially suspected that the two proteins might work together in a signaling complex to send a
stimulatory signal that would promote anchorage-independent
growth. However, we found that paxillin exerts a negative regulatory effect on this transformed growth phenotype, whereas
Cat-1, by binding to paxillin, is able to repress its negative regulatory activity and thereby promote anchorage-independent
growth. Thus, the inhibition of anchorage-independent growth
caused by knocking down Cat-1 expression in HeLa cells can be
overcome by knockdown of paxillin expression. Moreover,
these effects on anchorage-independent growth and transformation appear to be driven by changes in Akt activity. Specifically, knockdown of Cat-1 resulted in lower levels of Akt activation, whereas knocking down paxillin enhanced Akt activity.
We then found that expressing activated forms of Akt1 and
Akt2 was able to restore anchorage-independent growth in
cells where Cat-1 expression had been knocked down. Collectively, these results point to new and unexpected roles for Cat-1
and paxillin in the regulation of anchorage-independent
growth in human cervical carcinoma cells, whereby Cat-1 promotes this transformed phenotype by mitigating the negative
regulatory actions of paxillin.

Cat-1/Git-1 Binds Paxillin and Promotes AKT Activation

siRNA column with the Pxn siRNA 1 and 2 columns), with the
largest increase in colony formation being achieved when using
the paxillin siRNA that most effectively reduced paxillin
expression (i.e. Pxn siRNA 2, Fig. 1C).
An analogous set of experiments was carried out using
NIH3T3 mouse fibroblasts that were transformed by the stable expression of a constitutively active Cdc42 mutant
(Cdc42(F28L)), as we had found previously that these cells
exhibited anchorage-independent growth in a manner dependent on Cat-1, similar to human cervical carcinoma cell lines
(6). Control siRNA or Pxn siRNA 1 was introduced into fibroblasts expressing the activated Cdc42(F28L) mutant (Fig. 1D,
top panel), prior to the cells being placed in soft agar. Fig. 1E
shows that knocking down paxillin expression by 30%-50%
resulted in a corresponding increase in the amount of colonies
formed by NIH3T3 cells expressing Cdc42(F28L).
Because decreasing paxillin levels in HeLa cancer cells using
siRNAs promoted their ability to grow under anchorage-independent conditions, we then examined whether overexpressing
paxillin in these cells yielded the opposite effect. Compared
with cells expressing vector alone, the amount of colonies generated by HeLa cells ectopically expressing GFP-tagged wildtype paxillin (Fig. 2A, top panel, Pxn WT) was reduced by ⬃45%
MARCH 3, 2017 • VOLUME 292 • NUMBER 9

(Fig. 2B, compare the Vector and Pxn WT columns), which was
similar to the reduction in colonies observed when HeLa cells
were transfected with a V5-tagged dominant-negative form of
Cat-1 that is unable to function as an Arf GAP or bind paxillin
(6), referred to as Cat-1 KK-RA (Fig. 2, A, center panel, Cat-1
KK-RA, and B, compare the Cat-1 KK-RA and Pxn WT
columns).
The Binding of Cat-1 to Paxillin Reverses Its Negative Regulatory Effects on Anchorage-independent Growth—The findings
described in the preceding section suggest that paxillin might
function in certain types of cells (i.e. cervical carcinoma cells
and transformed fibroblasts) as a negative regulator of anchorage-independent growth. When considered together with our
previous findings that Cat-1 needs to interact with paxillin to
promote the growth of HeLa cells in soft agar (6), these results
raised the intriguing possibility that Cat-1, by binding to paxillin, represses a negative regulatory effect exerted by paxillin on
anchorage-independent cell growth. This further suggested
that the inability of HeLa cells to exhibit a transformed growth
phenotype under conditions where Cat-1 has been knocked
down should be reversed by the simultaneous knockdown of
paxillin. To directly investigate this possibility, we knocked
down the expression of Cat-1 alone versus knocking down both
Cat-1 and paxillin expression (Fig. 3A, compare the Cont.
siRNA lane with the Cat-1 siRNA and Cat-1 siRNA and Pxn
siRNA lanes) and then performed anchorage-independent
growth assays on the cells. As shown previously (6), knocking
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 2. The ectopic expression of paxillin in HeLa cells causes them to
lose their transformed phenotype. A and B, two sets of HeLa cells were
transfected with vector alone, GFP-tagged wild-type paxillin (Pxn WT), or
V5-tagged Cat-1 KK-RA. One set (A) was lysed and then immunoblotted with
GFP, V5, and actin antibodies. Soft agar assays were performed (B) on the
other set of cells. The number of colonies that formed for each condition was
determined. All of the experiments shown were performed three separate
times, each yielding similar results. The data shown in B represent mean ⫾
S.D. Student’s t tests were performed. *, p ⬍ 0.05.

FIGURE 3. The inability of HeLa cells depleted of Cat-1 to grow under
anchorage-independent conditions is restored by knocking down paxillin expression. A and B, two sets of HeLa cells were transfected with the
indicated combinations of Cont. siRNA, Cat-1 siRNA, and Pxn siRNA. One set
(A) was lysed and then immunoblotted with Cat-1 and paxillin antibodies.
Soft agar assays were performed (B) on the other set of cells. The number of
colonies that formed for each condition was determined. All of the experiments shown were performed three separate times, each yielding similar
results. The data shown in B represent mean ⫾ S.D. Student’s t tests were
performed. *, p ⬍ 0.05.

Cat-1/Git-1 Binds Paxillin and Promotes AKT Activation
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FIGURE 4. Paxillin, Cat-1, and activated AKT localize together in HeLa cells
grown under anchorage-independent conditions as spheres. HeLa cells
were cultured under anchorage-independent conditions by plating them on
bacteria-grade dishes and allowing them to form spheres in suspension. The
spheres were then collected and stained with the indicated combinations of
Pxn, Cat-1, and phospho-Akt (Ser-473) antibodies. As a negative control,
spheres of HeLa cells were also stained with only the fluorescently conjugated secondary antibodies (Green Secondary Ab and Red Secondary Ab). DAPI
was used to label nuclei. Arrows indicate some of the areas where paxillin
localizes with either Cat-1 or phospho-Akt (Ser-473). The experiments shown
were performed three separate times, each yielding similar results.

for inhibiting Akt activity. Lysates of HeLa cells expressing control siRNA or a Cat-1 siRNA were immunoblotted with an antibody that detects paxillin when it is phosphorylated at Tyr-118,
a major regulatory site (8, 11, 12). However, only a slight
increase in the levels of phosphorylated paxillin could be
detected in cells in which Cat-1 expression was knocked down
(Fig. 5D, top panel). The same experiment was also carried out
on HeLa cells maintained in suspension, a condition that more
closely reflects cells grown under anchorage-independent (soft
agar) conditions. As expected, the levels of paxillin phosphorylation at Tyr-118 dramatically decreased in suspended cells
expressing control siRNA compared with the same cells grown
attached to a culture plate (Fig. 5E, first panel, compare the
Attached cells expressing Cont. siRNA lane with the Suspended
cells expressing Cont. siRNA lane). The phosphorylation of paxillin in suspended HeLa cells depleted of Cat-1 expression did
not change (Fig. 5E, first panel, compare the Suspended cells
VOLUME 292 • NUMBER 9 • MARCH 3, 2017
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down Cat-1 expression in HeLa cells markedly reduced their
ability to form colonies in soft agar (Fig. 3B, compare the Cont.
siRNA and Cat-1 siRNA columns). However, under conditions
where both Cat-1 and paxillin expression was knocked down,
HeLa cells again formed colonies nearly as well as cells expressing the control siRNA (Fig. 3B, Cat-1 siRNA and Pxn siRNA).
These findings are consistent with the idea that Cat-1 binds
paxillin and represses its ability to inhibit anchorage-independent growth.
Cat-1 Maintains Akt Activation—We next set out to better
understand how the formation of Cat-1䡠paxillin complexes positively supported anchorage-independent cell growth. Various
intracellular signaling events have been implicated in the
growth and survival responses required for cells to grow under
anchorage-independent conditions, with one of the more common examples being the activation of the mTOR complex 1 and
2 (mTORC1 and mTORC2)-Akt pathway (20). To determine
whether the binding of Cat-1 to paxillin could alter the activation of this pathway, HeLa cells were grown in suspension, and
the resulting spheres that formed were stained with various
combinations of antibodies that recognize paxillin, Cat-1, and
Akt when it is phosphorylated at Ser-473. As a negative control,
spheres were also stained with only the fluorescently conjugated secondary antibodies. Fig. 4 shows that very low levels of
signal were detected in spheres stained with the secondary antibodies (Green or Red Secondary Ab), whereas paxillin appeared
as small puncta throughout the cytosol of many of the HeLa
cells that comprised the spheres (Pxn). Importantly, both Cat-1
(Fig. 4, Cat-1) and phosphorylated Akt (Fig. 4, P-Akt (Ser473))
localized with paxillin, suggesting that there might be a functional connection between these proteins.
We next introduced control siRNA or a Cat-1-targeted
siRNA into HeLa cells and then analyzed the lysates generated
from these cells by Western blotting analysis using antibodies
that detect the phosphorylated (activated) forms of Akt and
ERK, another protein that is important for mediating the
anchorage-independent growth of some cancer cell types (20).
Although we were unable to consistently detect changes in ERK
activation following knockdown of Cat-1 in these cells (Fig. 5A,
third panel, compare the Cont. siRNA and Cat-1 siRNA lanes),
the phosphorylation levels of Akt at Ser-473 were significantly
reduced (Fig. 5A, first panel, compare the Cont. siRNA and
Cat-1 siRNA lanes). Akt phosphorylation was then restored by
knocking down paxillin expression in cells that were already
depleted of Cat-1 (Fig. 5A, first panel, compare the Cat-1 siRNA
and Cat-1 and Pxn siRNA lanes). Interestingly, HeLa cells in
which only paxillin was knocked down showed a much greater
degree of phosphorylated Akt than their counterparts expressing control siRNA (Fig. 5B, top panel). These findings, combined with the fact that Akt phosphorylation is reduced in HeLa
cells ectopically expressing wild-type paxillin (Fig. 5C, top
panel), suggests that paxillin in some way imparts a negative
regulation of Akt activation that can be abrogated upon binding
of Cat-1 to paxillin.
Because the phosphorylation state of paxillin has been shown
to influence its ability to regulate some cellular processes
(i.e. promote focal complex turnover) (8 –12), we determined whether paxillin phosphorylation might be important

Cat-1/Git-1 Binds Paxillin and Promotes AKT Activation

FIGURE 5. The levels of Akt phosphorylation are dependent on Cat-1 and
paxillin expression. A, HeLa cells transfected with the indicated combinations of Cont. siRNA, Cat-1 siRNA, and Pxn siRNA were lysed and then immunoblotted with phospho-Akt (Ser-473), Akt, phospho-ERK, and ERK antibodies. B, HeLa cells transfected with either control siRNA or paxillin siRNA were
lysed and then immunoblotted with phospho-Akt (Ser-473) and Akt antibodies. C, HeLa cells transfected with either the vector-alone (Vector) or GFPtagged wild-type paxillin (Pxn WT) were lysed and then immunoblotted with
phospho-AKT (Ser-473) and Akt antibodies. D, HeLa cells transfected with
either Cont. siRNA or Cat-1 siRNA were lysed and then immunoblotted
with phospho-Pxn (Tyr-118) and Pxn antibodies. E, HeLa cells transfected with
either Cont. siRNA or Cat-1 siRNA were grown in a monolayer (Attached) or
placed in suspension (Suspended) before being lysed and immunoblotted
with phospho-Pxn (Tyr-118), Pxn, phospho-Akt (Ser-473), and Akt antibodies.
All of the experiments shown were performed three separate times, each
yielding similar results. The relative changes in ERK and AKT phosphorylation
for each condition in A and B was determined.

expressing Cont. siRNA lane with the Suspended cells expressing
Cat-1 siRNA lane) even though Akt phosphorylation decreased
under these same conditions (Fig. 5E, third panel). Thus,
changes in the phosphorylation state of paxillin do not appear
to be directly responsible for its ability to negatively regulate the
activation of Akt in HeLa cells.
We then determined whether the effect of knocking down
Cat-1 expression on the phosphorylation of Akt was specific for
a particular Akt isoform. The Akt family of proteins is made up
of three highly related members, Akt1, Akt2, and Akt3. Akt1
and Akt2 are ubiquitously expressed and have been linked to
promoting cell growth and survival responses, whereas Akt3 is
expressed primarily in the brain (21), making it unlikely that
this isoform would be playing a role in cervical carcinoma cells.
Thus, we focused on Akt1 and Akt2. The lysates collected from
HeLa cells expressing either control siRNA or Cat-1-targeted
MARCH 3, 2017 • VOLUME 292 • NUMBER 9

siRNA (Fig. 6A) were immunoblotted with Akt1- and Akt2specific antibodies. Under conditions where Cat-1 expression
was markedly reduced (Fig. 6A, top panel, Cat-1 siRNA), the
overall levels of Akt1 and Akt2 were unchanged (Fig. 6A, center
and bottom panels, compare the Cont. siRNA and Cat-1 siRNA
lanes). To determine the extent to which each Akt isoform was
activated, the same cell lysates were then probed with antibodies that can distinguish between Akt1 and Akt2 when they are
phosphorylated at Ser-473. Fig. 6B shows that, under conditions where Cat-1 expression was knocked down in HeLa cells,
the phosphorylation levels of Akt1 (left panel) and Akt2 (right
panel) were decreased, suggesting that Cat-1 regulates the
activity of both of these Akt isoforms.
Akt Activation Is Necessary for Anchorage-independent
Growth—We next examined whether Akt activity was important for the Cat-1-mediated anchorage-independent growth of
HeLa cancer cells by knocking down either Akt1 or Akt2, individually or in combination (Fig. 7A), and assaying their ability to
form colonies in soft agar. HeLa cells expressing control siRNA
(as a positive control) or Cat-1 siRNA (as a negative control)
were also assayed. Knocking down the expression of either Akt
isoform reduced the amount of colonies formed in soft agar,
although knockdown of Akt2 consistently had a greater effect
(Fig. 7B, compare the Cont. siRNA column with the Akt1 siRNA
and Akt2 siRNA columns). Interestingly, simultaneous knockdown of both Akt1 and Akt2 or treatment of HeLa cells with an
Akt inhibitor (Akt inhibitor VIII), a cell-permeable inhibitor
that blocks both Akt isoforms, decreased colony formation by
HeLa cells to a similar extent as knocking down Cat-1 (Fig. 7B,
compare the Cont. siRNA column with the Akt1 plus Akt2
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 6. Cat-1 regulates the phosphorylation of both Akt1 and Akt2. A,
HeLa cells transfected with either Cont. siRNA or Cat-1 siRNA were lysed and
then immunoblotted with Cat-1, Akt1, and Akt2 antibodies. B, the same cell
lysates generated in A were further immunoblotted with antibodies that specifically detect phospho-Akt1 (Ser-473) and Akt1 (left panel) and phosphoAkt2 (Ser-473) and Akt2 (right panel). All of the experiments shown were performed three separate times, each yielding similar results. The relative
changes in Akt1 and Akt2 phosphorylation for each condition in B was
determined.

Cat-1/Git-1 Binds Paxillin and Promotes AKT Activation

siRNA and Akt inhibitor VIII columns). These results suggest
that the role of Cat-1 in helping maintain the activation of Akt
is necessary for the anchorage-independent growth of HeLa
cells.
We then went on to determine whether maintaining Akt
activity in HeLa cells, under conditions where Cat-1 was
knocked down, restored their ability to exhibit anchorage-independent growth. Specifically, we tested constitutively active
forms of Akt1 and Akt2 in which aspartic acid residues replaced
Thr-308 and Ser-473, i.e. the key residues that need to be phosphorylated for activation (20 –23). The cells were then transfected with siRNAs targeting Cat-1 and assayed for colony formation in soft agar to see whether the constitutively active
Akt mutants could reverse the inhibition of colony formation
caused by knocking down Cat-1 expression. Fig. 8, A and B,
shows that the expression of a phosphomimetic Akt1 or Akt2
mutant in cells where endogenous Cat expression had been
knocked down, gave rise to a partial recovery of the ability of
HeLa cells to grow in soft agar. However, co-expression of the
phosphomimetic Akt1 and Akt2 mutants in HeLa cells in which
Cat-1 expression was knocked down led to a complete rescue of
anchorage-independent growth (Fig. 8B, compare the Cat-1
siRNA column with the Cat-1 siRNA plus Akt1 DD and Akt2 DD
columns).
Cat-1 Mediates an Inverse Relationship between Akt and
p70S6 Kinase Activation—These results indicate that Akt
activation plays a key role in the ability of Cat-1 to promote

3952 JOURNAL OF BIOLOGICAL CHEMISTRY

FIGURE 8. The block in HeLa cell transformation caused by the depletion
of Cat-1 is rescued by the ectopic expression of activated forms of AKT. A
and B, two sets of HeLa cells stably expressing the indicated combinations of
the vector alone and constitutively active forms of Akt1 (Akt1 DD) and Akt2
(Akt2 DD) were transfected with either Cont. siRNA or Cat-1 siRNA. One set (A)
was lysed and then immunoblotted with Cat-1 and HA antibodies. The vertical lines represent a portion of the blots that were cropped. Soft agar assays
were performed (B) on the other set of cells. The number of colonies that
formed for each condition was determined. All of the experiments shown
were performed three separate times, each yielding similar results. The data
shown in B represent mean ⫾ S.D. Student’s t tests were performed. *, p ⬍
0.05; **, p ⬍ 0.01.

anchorage-independent growth, although the molecular mechanism linking Cat-1 to Akt was unknown. However, we found
that, in HeLa cells, there was an inverse relationship between
the activation of Akt and p70S6 kinase so that when Akt activation was reduced as a result of knocking down Cat-1 expression, there was a concomitant increase in p70S6 kinase activation (Fig. 9A, first and third panels, Cat-1 siRNA). The opposite
was true when paxillin expression was knocked down; Akt
activity was increased, whereas the activating phosphorylation
of p70S6 kinase was decreased (Fig. 9A, first and third panels,
Pxn siRNA). These results are consistent with findings that
show that excessive mTORC1-p70S6 kinase activity leads to
the down-regulation of PI3 kinase and, in turn, mTORC2 and
Akt (22, 23).
We hypothesized that the down-regulation of Akt activity in
HeLa cells where Cat-1 expression had been knocked down was
caused by the up-regulation of p70S6 kinase activity. This led us
to examine whether treating cells in which Cat-1 expression
had been knocked down with rapamycin to reduce mTORC1
and p70S6 kinase activation would restore Akt activity. Indeed,
rapamycin treatment restored Akt activation in cells where
Cat-1 expression was knocked down (Fig. 9B, first panel, compare the Cat-1 siRNA lane with the Cat-1 siRNA plus RapaVOLUME 292 • NUMBER 9 • MARCH 3, 2017
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FIGURE 7. Akt1 and Akt2 contribute to the anchorage-independent
growth of HeLa cells. A and B, two sets of HeLa cells were transfected with
the indicated combinations of Cat-1 siRNA, Akt1 siRNA, and Akt2 siRNA or
treated with Akt inhibitor VIII (2 M). One set (A) was lysed and then immunoblotted with Akt1 and Akt2 antibodies. Soft agar assays were performed (B)
on the other set of cells. The number of colonies that formed for each condition was determined. All of the experiments were performed three separate
times, each yielding similar results. The data shown in B represent mean ⫾
S.D. Student’s t tests were performed. *, p ⬍ 0.05; **, p ⬍ 0.01.

Cat-1/Git-1 Binds Paxillin and Promotes AKT Activation

mycin lane). As further confirmation that the mTORC1-p70S6
kinase negative feedback loop is responsible for mediating this
effect, we found that treatment of cells depleted of Cat-1
expression with INK 128 to block the activation of both
mTORC1 and mTORC2 effectively ablated the phosphorylation of p70S6 kinase as well as that of Akt (Fig. 9B, first and third
panels, Cat-1 siRNA plus INK). Next, we examined whether the
restoration of Akt activity by rapamycin treatment is sufficient
to reverse the blockage of anchorage-independent growth
caused by knocking down Cat-1 expression. In fact, we found
that treating HeLa cells where Cat-1 expression had been
knocked down with rapamycin restored most of the anchorageindependent growth (Fig. 9C, compare the Cat-1 siRNA and
Cat-1 siRNA plus Rapamycin columns). These results suggest
that Cat-1 and potentially paxillin are regulating p70S6 kinase
activity at the level of mTORC1.
Cat-1 Influences mTORC1/p70S6 Kinase through Its Regulatory Effects on the Arf1 GTPase—How is Cat-1 able to negatively
influence mTORC1 activity and, in turn, increase the levels of
MARCH 3, 2017 • VOLUME 292 • NUMBER 9

Discussion
Cat-1 is a GAP that can inactivate members of the Arf
GTPase family (i.e. Arf1 and Arf6). It also serves as a protein
scaffold that has the potential to interact with a variety of binding partners, including Cool-1/␤-Pix-1 and paxillin (1–3).
Although Cat-1 is best known for its roles in regulating cell
morphology and promoting cell migration (2, 29, 30), there has
been accumulating evidence suggesting that Cat-1 can also
contribute to several different aspects of cancer progression.
For example, Cat-1 has been shown to be important for highly
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FIGURE 9. Paxillin inhibits Akt activity through an mTORC1-mediated
negative feedback loop. A, HeLa cells transfected with the indicated combinations of Cont. siRNA, Cat-1 siRNA, and Pxn siRNA were lysed and then
immunoblotted with phospho-Akt (Ser-473), Akt, phospho-p70S6 kinase
(p-S6K), and p70S6 kinase (S6K) antibodies. B and C, two sets of HeLa cells were
treated with the indicated combinations of Cont. siRNA, Cat-1 siRNA, rapamycin, and INK 128 (INK). One set (B) was lysed and then immunoblotted with
phospho-Akt (Ser-473), Akt, phospho-p70S6 kinase, and p70S6 kinase antibodies. Soft agar assays were performed (C) on the other set of cells. The
number of colonies that formed for each condition was determined. All of the
experiments shown were performed three separate times, each yielding similar results. The relative changes in Akt and p70 S6 kinase phosphorylation for
each condition in A and B was determined, whereas the data shown in C
represent mean ⫾ S.D. Student’s t tests were performed. *, p ⬍ 0.05; **, p ⬍
0.01.

Akt activity? Recent reports indicated that the Arf1 GTPase is
capable of mediating the activation of mTORC1 (24, 25). Given
that Cat-1 is a negative regulator of Arf1 GTPase activity by
serving as a GAP (4, 5, 6), we hypothesized that Cat-1 might
influence mTORC1 activity through its ability to negatively
regulate Arf1. To test this idea, we monitored the levels of phosphorylated p70S6 kinase as a measure of mTORC1 activity in
cells where Cat-1 expression had been knocked down and compared them with p70S6 kinase activity in cells where both Cat-1
and Arf1 had been knocked down. We found that knocking
down both Cat-1 and Arf1 expression reduced the phosphorylation levels of p70S6 kinase so that they were comparable with
those found in HeLa cells treated with just control siRNA (Fig.
10A, third panel, compare the Cat-1 siRNA and Cat-1 siRNA
plus Arf1 siRNA lanes). This reduction in phospho-p70S6
kinase levels was accompanied by an increase in Akt activation
(Fig. 10A, first panel, compare the Cat-1 siRNA and Cat-1 siRNA
plus Arf1 siRNA lanes) as well as a restoration of anchorage-independent growth (Fig. 10B, compare the Cat-1 siRNA and Cat-1
siRNA plus Arf1 siRNA columns).
Thus, these findings suggest a mechanism by which Cat-1,
through the negative regulation of Arf1 and a corresponding
reduction in mTORC1 signaling to p70S6 kinase, resulted in
the activation of Akt, thereby contributing a positive signal for
anchorage-independent growth. We then asked how paxillin fit
into this picture. Given that Cat-1 and paxillin undergo a direct
interaction (26), we suspected that paxillin may be regulating
the mTOR/Akt pathway by influencing the activation of Arf1.
Thus, we monitored the cellular activation of Arf1 under different conditions where we knocked down Cat-1 and paxillin by
using a pulldown assay that takes advantage of the ability of
GTP-bound Arf1 to bind specifically to its signaling effector,
GGA3. As expected, we found that knocking down Cat-1
expression led to a marked increase in GTP-bound (activated)
Arf1 in HeLa cells (Fig. 10C, top panel, compare the Cont.
siRNA and Cat-1 siRNA lanes). However, the majority of the
increase in the levels of activated Arf1 that accompanied the
knockdown of its negative regulator Cat-1 was lost when paxillin expression was knocked down together with Cat-1 (Fig.
10C, compare the Cat-1 siRNA and Cat-1 siRNA plus Pxn
siRNA lanes). Concomitantly, there was a corresponding
decrease in phospho-p70S6 kinase and an increase in phosphorylated Akt (Fig. 9A). We are currently further investigating how
this might occur, although one intriguing possibility is a role for
paxillin in promoting Arf1 activation through its ability to
interact with the Arf guanine nucleotide exchange factor Arf
nucleotide-binding site opener (ARNO) (27, 28).
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aggressive forms of breast (31), lung (32), and oral cancers (33)
to metastasize to secondary sites as well as for the growth of
liver and colon cancer cells (34). Moreover, we have recently
shown that Cat-1 is overexpressed in a large majority of cervical
carcinomas and is essential for the HeLa cervical cancer cell line
to grow under anchorage-independent conditions. However,
the mechanisms through which Cat-1 mediates its effects, especially as they pertain to the growth of cancer and transformed
cells, are still not well understood.
Here we show that Cat-1 promotes the anchorage-independent growth of HeLa cells as well as fibroblasts that are transformed through the ectopic expression of an activated Cdc42
mutant as an outcome of its ability to interact with paxillin.
Given the several connections linking paxillin to cancer progression (13–18), we initially assumed that Cat-1 and paxillin
worked together to send a stimulatory signal that promoted this
transformed phenotype. Instead, however, we discovered that
Cat-1 interacts with paxillin to negatively regulate mTORC1/
p70S6 kinase activation to an extent that ensures maximal acti-
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vation of the cell growth/survival protein Akt (35). A working
model that is consistent with the results we have obtained thus
far is presented in Fig. 11. In this model, the role of Cat-1 is to
antagonize the positive regulation of Arf1 by paxillin and
thereby prevent it from signaling the activation of mTORC1
and p70S6 kinase, which, in turn, removes a negative regulation
of mTORC2 and Akt normally mediated by activated p70S6
kinase. Thus, the positive actions of Cat-1 on Akt activation
and, ultimately, anchorage-independent growth are an outcome of Cat-1 binding to paxillin and exerting its Arf-GAP
activity, which would reverse any activation of Arf1 induced by
paxillin alone. Knocking down Cat-1 has a negative effect on
anchorage-independent growth through the loss of its antagonistic properties on the Arf1-mTORC1-p70S6 kinase pathway.
However, knocking down paxillin removes a positive stimulatory input into this pathway (i.e. by eliminating the paxillinmediated activation of Arf1) and thereby eliminates the deleterious effects caused by knocking down Cat-1. It is interesting to
note that this newly described role for Cat-1 is similar to that of
VOLUME 292 • NUMBER 9 • MARCH 3, 2017
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FIGURE 10. The block in HeLa cell transformation caused by the depletion of Cat-1 is rescued by knocking down Arf1. A and B, two sets of HeLa cells were
transfected with the indicated combinations of Cont. siRNA, Cat-1 siRNA, and Arf1 siRNA. One set (A) was lysed and then immunoblotted with phospho-Akt
(Ser-473), Akt, phospho-p70S6 kinase, and p70S6 kinase antibodies. Soft agar assays were performed (B) on the other set of cells. The number of colonies that
formed for each condition was determined. C, HeLa cells transfected with the indicated combinations of Cont. siRNA, Cat-1 siRNA, and Pxn siRNA were lysed
and then used in pulldown assays using the Golgi-associated, ␥ adaptin ear-containing, Arf-binding protein 3 (GGA3)-GST fusion protein prebound to beads.
The cell lysates (Input) as well as the cell lysate proteins that bound the GGA3 fusion protein (GGA3 pulldown) were immunoblotted with an Arf1 antibody. All
of the experiments shown were performed three separate times, each yielding similar results. The relative changes in Akt phosphorylation for each condition
in A and Arf1 activation in C were determined. The data shown in B represent mean ⫾ S.D. Student’s t tests were performed. *, p ⬍ 0.05; **, p ⬍ 0.01.
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DEP domain-containing mTOR-interacting protein (DEPTOR),
a protein that was identified as an inhibitor of mTORC1 activation (36). When overexpressed in multiple myeloma cells,
DEPTOR promotes cell survival by suppressing mTORC1
activity and promoting Akt activity.
It seems likely that the positive and negative inputs provided
by paxillin and Cat-1 into the Arf1-mTORC1-p70S6 kinase
pathway need to be very carefully balanced. Moreover, it is easy
to imagine how, in some types of cancers, the stimulatory input
provided by paxillin into the mTORC1/p70S6 kinase pathway
may have a positive role in cancer cell growth and survival, as
has sometimes been reported. Our future efforts will be
directed toward understanding how the Cat-1-mediating signaling balance outlined in Fig. 11 is achieved in different contexts of malignant transformation as well as identifying additional proteins that play a role in this pathway. It will also be
important to learn more about how Akt contributes stimulatory signals to the ability of cancer cells to exhibit anchorageindependent growth.

Experimental Procedures
Reagents—The Cat-1/Git-1 (catalog no. sc-13961), Arf1 (catalog no. sc-53168), and GFP (catalog no. sc-8334) antibodies
were purchased from Santa Cruz Biotechnology and used at
1:500 dilutions. The phospho-p70S6 kinase (catalog no. 9205),
p70S6 kinase (catalog no. 9202), phospho-Akt (Ser-473, catalog
no. 4060), pan-Akt (catalog no. 9272), Akt1 (catalog no. 2938),
Akt2 (catalog no. 2964), phospho-Akt1 (Ser-473, catalog no.
9018), phospho-Akt2 (Ser-474, catalog no. 8599), phosphoERK (catalog no. 4370), ERK (catalog no. 9102), V5 (catalog no.
13202), HA (catalog no. 3724), actin (catalog no. 8456), and
phospho-paxillin (Tyr-118, catalog no. 2541) primary antibodies as well as the mouse and rabbit IgG horseradish peroxidaseconjugated secondary antibodies (catalog nos. 7074 and 7076,
respectively), were from Cell Signaling Technology and used at
1:2000 dilutions. The paxillin antibody (catalog no. 05-417) was
from EMD Millipore and used at a 1:1000 dilution. AKT inhibitor VIII (catalog no. 124018) and rapamycin (catalog no.
MARCH 3, 2017 • VOLUME 292 • NUMBER 9
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FIGURE 11. Diagram showing a plausible mechanism through which
Cat-1 functions in HeLa cells to promote cellular transformation. Cat-1
binds to paxillin to abrogate its actions as a negative regulator of anchorageindependent growth (left). Specifically, the interaction between Cat-1 and
paxillin perturbs the ability of paxillin to activate the Arf1-mTORC1-p70S6
kinase pathway, which ensures that the necessary level of AKT activation
needed for supporting anchorage-independent growth (i.e. colony formation in soft agar) is met. However, under conditions where Cat-1 is knocked
down (right), the Arf1-mTORC1-p70S6 kinase pathway is activated, leading to
a p70S6 kinase-mediated negative regulation of Akt activity and loss of
anchorage-independent growth.

553210) were also from EMD Millipore and used at 0.2 M and
0.1 M, respectively. INK 128 (catalog no. S2811) was from Selleckchem and used at 0.5 M. The precast 4 –20% Tris/glycine
acrylamide gels were from Thermo Fisher Scientific. The PVDF
transfer membrane and the Western Lighting Plus ECL reagent
were from PerkinElmer Life Sciences. The protein G-agarose
beads and all cell culture reagents, including RPMI 1640
medium, DMEM, calf serum, FBS, Lipofectamine, and puromycin, as well as the control siRNA and siRNAs targeting Cat-1,
paxillin, Akt1, Akt2, and Arf1, were purchased from Invitrogen.
Plasmids—The V5-tagged pcDNA3 expression construct
encoding a dominant negative form of rat Cat-1 (Cat-1 KK-RA),
the pEGFP expression construct encoding chicken paxillin, and
the HA-tagged lentiviral vector pCDH-CMV-MOS-EF1-Puro
(System BioSciences) encoding human Akt1 and Akt2 were generated previously (6). The constitutively active mutant forms of
Akt1, termed Akt1 DD (T308D/S473D), and Akt2, termed Akt2
DD (T309D/S474D), were generated using the QuikChangeTM
site-directed mutagenesis kit (Stratagene).
Lentivirus Generation—The HA-tagged lentiviral vector
pCDH-CMV-MOS-EF1-Puro encoding wild-type and mutant
forms of Akt1 and Akt2 were transfected into HEK293T cells
using Lipofectamine (Invitrogen). The mature lentiviruses shed
into the culturing medium from the transfectants were collected and processed according to the instructions of the manufacturer (System BioSciences).
Cell Culture—HeLa cells were grown in RPMI 1640 medium
containing 10% FBS, whereas NIH3T3 cells stably expressing
an activated form of Cdc42 (Cdc42 F28L) were grown in
DMEM containing 10% calf serum. The siRNAs and the expression constructs encoding various forms of Cat-1 and paxillin
were transfected into cells using Lipofectamine, whereas the
Akt constructs were introduced into cells via lentiviral infection. HeLa cells expressing HA-tagged forms of Akt were
selected for and maintained by supplementing the growth
medium with 0.175 g/ml puromycin. As indicated, cells were
treated with 2.0 M AKT inhibitor VIII, 0.1 M rapamycin, and
0.5 M INK 128.
Immunofluorescence—HeLa cells grown on glass coverslips
were either mock-transfected, or transfected with a construct
encoding GFP-tagged wild-type paxillin. In certain cases, HeLa
cells were also grown under anchorage-independent conditions
by plating them on bacteria-grade dishes and allowing them to
form spheres. The cells grown on coverslips or in suspension as
spheres were fixed with 3.7% formaldehyde, permeabilized with
PBS containing 0.1% Triton X-100, and then blocked with 10%
bovine serum albumin diluted in PBS. The cells were incubated
with GFP, phospho-Akt (Ser-473), and Cat-1 antibodies at
1:500 dilutions, whereas the paxillin clone 165 antibody (catalog no. 610620) from BD Biosciences was used at a 1:200 dilution. The primary antibodies were detected using Alexa Fluor
488-conjugated anti-mouse (catalog no. A-11034) and Rhodamine-conjugated anti-rabbit (catalog no. R-6394) secondary
antibodies from Molecular Probes at 1:800 dilutions. DAPI was
used to label nuclei. Digital images of the cells were captured
using a Zeiss fluorescence microscope outfitted with a Sensicam qe camera (Cooke Co.) and processed using IPLABS software (BD Biosciences).
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Immunoblot Analysis—Cells were lysed with cell lysis buffer
(25 mM Tris (pH 7.4), 100 mM NaCl, 1% Triton X-100, 1 mM
EDTA, 1 mM DTT, 1 mM NaVO4, 1 mM ␤-glycerol phosphate, 1
mM aprotinin, 1 mM leupeptin, and 1 mM PMSF). The lysates
were resolved by SDS-PAGE, and then the proteins were transferred to PVDF membranes. The membranes were incubated
with the indicated primary antibodies diluted in 20 mM Tris
(pH 7.4), 135 mM NaCl, and 0.02% Tween 20. The primary
antibodies were detected with horseradish peroxidase-conjugated secondary antibodies followed by exposure to ECL reagent.
Immunoprecipitations—Cell extracts (typically 500 g of
each) were incubated with primary antibodies for 2 h at 4 °C
with rotation. Protein G-agarose beads were then added to the
lysates for an additional hour, at which point the beads were
washed extensively with cell lysis buffer before being resuspended in Laemmli sample buffer and boiled.
Soft-agar Assays—HeLa cells and NIH3T3 cells stably expressing Cdc42 F28L, transfected with various siRNAs or
expression plasmids or infected with a lentivirus as indicated,
were plated at a density of 5 ⫻ 103 cells/ml in medium containing 0.3% agarose onto underlays composed of growth medium
containing 0.6% agarose in 6-well dishes. The cultures were fed
once a week, and, after 14 days, the colonies were counted.
Arf GTPase Activity Assays—A GST fusion protein containing the N-terminal portion of Golgi-associated, ␥ adaptin earcontaining, Arf-binding protein 3 bound to a glutathione resin
was purchased from Pierce. The activity assays were performed
according to the instructions of the manufacturer.
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